Recruiting

Testing a new drug combination for advanced stomach cancer

Plain-English translation of NCT05640609 on ClinicalTrials.gov ↗ · Source last updated May 2023 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new treatment approach for advanced stomach cancer that has spread or come back after surgery. The treatment combines three medications: chemotherapy (Capeox), an immunotherapy drug called sintilimab, and bevacizumab (a medication that blocks blood vessel growth to tumors). Researchers want to see if this combination is safe and effective as a first-line treatment for eligible patients.

Current standard treatments for advanced stomach cancer help patients live about one year on average, and doctors are looking for better options. This trial exists because early studies suggest that combining these three medications might work better than existing approaches, but this specific combination hasn't been properly tested in patients yet.

Do you qualify?

You likely qualify if…

you have been diagnosed with adenocarcinoma of the stomach or gastroesophageal junction (confirmed by biopsy or imaging)
your cancer is unresectable (cannot be removed by surgery), recurrent (has come back), or metastatic (has spread to other parts of your body)
you are between 18 and 70 years old
you have not received chemotherapy or other systemic anti-cancer treatment for advanced disease (though you may have had treatment 6+ months ago that has stopped)
you have at least one measurable tumor lesion that doctors can evaluate
your major organ function (blood counts, liver, kidneys, and blood clotting) is normal or near-normal

You likely don't qualify if…

you have received chemotherapy or other systemic treatment for advanced stomach cancer in the past (unless completed more than 6 months before this trial)
you have received palliative radiation therapy within 2 weeks before starting the trial
you are pregnant or nursing
you have severely impaired kidney, liver, or bone marrow function
you are currently taking anti-tumor herbal or traditional Chinese medicine (must stop at least 2 weeks before starting)

What participation looks like

You would receive the three-medication combination (chemotherapy, sintilimab, and bevacizumab) as your first treatment for advanced stomach cancer. The trial involves regular visits to the hospital where you'll receive treatment, have blood tests and imaging scans to monitor how the cancer responds, and be watched carefully for any side effects. The study will track your progress and overall survival to see if this new combination works better than standard treatments for people with your type of cancer.

AI-generated summary from trial data · Jun 10, 2026 · Not medical advice

Trial locations(1 site)

China

Liu Ming, Chengdu